Takeda best selling drug Velcade key patent is invalid

Source: Biovalley, August 26, 2015 In recent years, the cancer drug development department of Takeda pharmaceutical industry has suffered a lot The company's development of the lymphatic cancer drug alisertib and prostate cancer drug orteronel clinical research has failed to let investors have doubts about the innovation ability of Takeda R & D department Takeda recently announced that ixazomib, a new leukaemia treatment that the company hopes for, has been submitted to the relevant EU pharmaceutical departments for approval The relevant EU departments said they would take accelerated approval measures for the new drug The good news for the Japanese pharmaceutical giant is a long drought Takeda has high expectations for ixazomib, which it hopes will replace veclade in the future, which will lose patent protection in 2022 (related reading: Velcade has a new drug for Takeda leukaemia submitted to the European Union for review.) however, there is an unexpected situation Maybe Takeda pharmaceutical needs to change its plan now A recent decision from a US court will shorten Takeda's existing veclade patent protection to 2017 This also means that veclade will face strong challenges in the generic market in less than two years Velcade is a blockbuster star drug owned by Takeda pharmaceutical In the first quarter of this year, the sales volume of the drug in the U.S market reached 340 million dollars (the overseas market is sold by Johnson and Johnson) It can be imagined that the judgment of the U.S court will completely disrupt Takeda pharmaceutical's plan Christophe Weber, the first non Japanese CEO in Takeda pharmaceutical's history, is also under great pressure Since taking over as head of Takeda at the beginning of this year, Takeda has been plagued by poor performance and research and development failures A financial report in May this year showed that Takeda pharmaceutical was in a state of loss, which has also caused Weber to suffer Although Weber has repeatedly promised that Takeda pharmaceutical will soon usher in a turning point, this major setback may affect Weber's plan to revive Takeda pharmaceutical.